Final report of a consensus interferon (CIFN) plus ribavirin (RBV) study for chronic hepatitis C (CHC)
I. Zagni, Giovanna Fattovich(University of Modena and Reggio Emilia), Martina Felder(Ospedale di Bolzano), C. Paternoster, G. Mazzella(University of Bologna), C. Scattolini, A. Miracolo(University of Bologna), M. Pantalena, Caterina Rizzo(University of Pisa), S. Suppressa(Azienda Usl 8 Arezzo), Stefano Milani(University of Florence), Stefania Boccia(Università Cattolica del Sacro Cuore), P. Benedetti(Ospedale San Bortolo), P. Pignalosa, P. Rovere(Azienda Ospedaliera Ospedale Civile di Legnano), A. Tagger(University of Milan), Antonio Carlotto, Pedro Marques da Costa(University of Lisbon), Angelo Rossini(Centro Universitário Barão de Mauá), M.L. Ribero(University of Milan), L. Lomonaco, E. Minóla(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), C Ferrara(Presidio Ospedaliero), T. Bertin(Ospedale San Bortolo)
Unknown
January 1, 2003
Cited by 0
Related Papers
Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
|Gastroenterology|1997|1.4k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
ChatGPT and the rise of large language models: the new AI-driven infodemic threat in public health
|Frontiers in Public Health|2023|640
Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy
|European Journal of Epidemiology|2020|504